AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
The price of failure: Dutch company's chip monopoly born from a bad bet by Intel
4
Google employees arrested following protest over Israel ties at executive’s office
5
Cyber unicorn Armis acquiring Silk Security for $150 million
More news

Teva

20 stories about Teva
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
מניית טבע בורסת ניו יורק מניה

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach
The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva expects lower profits in 2024 despite a strong Q4 performance

31.01.24|Reuters
"We are gaining momentum, and now it's about executing as we did in 2023 in 2024," said CEO Richard Francis
ריצ'רד פרנסיס מנכ"ל טבע

Teva CEO: Israel’s production capacity has not been affected by the war

08.11.23|Sophie Shulman
The Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.
יונתן קולבר, מנהל שותף של ION מפעל טבע בכפר סבא

$300 million Teva bet: Will Norway's wealth fund and ION regret investing in the pharma giant?

11.09.23|Almog Azar
ION, which manages investments for the Norwegian wealth fund, began a buying spree of Teva shares at the beginning of the year
מפעל טבע בקנדה

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva profit plummets, stock slides

10.05.23|Reuters
Teva plans to unveil a new strategy next week which CEO Francis said would "build on Teva's strong foundations, key strengths, and sets the stage for long-term growth"
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
מנכל טבע ריצ'רד פרנסיס

Teva names Richard Francis as new CEO after Kåre Schultz departure

21.11.22|CTech
Francis is the former CEO of Sandoz and was also a senior executive at Biogen for 13 years
קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

Why are investors so pleased about Teva's $4.35 billion opioid settlement?

27.07.22|Sophie Shulman
The settlement removes the cloud of uncertainty that hovered over Teva, which on the one hand prevented investors from placing trust in its stock, while on the other hand also prevented Teva management from making substantial moves
חוגו חדש חברת תרופות טבע

Teva reaches $4.35 billion settlement in U.S. opioid lawsuits, shares surge

27.07.22|Sophie Shulman and Reuters
Teva is set to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone
Amalia Adler-Waxman Teva Pharmaceuticals 20

“You have to walk the talk and have proof for everything that you say.”

08.02.22|CTech
Now vice president of Environmental, Social and Governance at Teva Pharmaceuticals, Amalia Adler-Waxman says that doing good requires being conscious and strategic
אסף ברנע 2

Ichilov Hospital and Sanara Ventures to join forces to promote innovation in neurology

12.10.21|CTech
The investment platform will invest in the hospital’s innovative technologies, giving it the opportunity to identify early-stage startups in the fields of neurology, digital health
שואה זיכרון יום השואה אושוויץ

Holocaust memorial event March of the Living goes virtual because of Covid-19

07.04.21|CTech
In honor of Holocaust Memorial Day, the annual march to former Auschwitz concentration camp to commemorate survivors will be hosted in an online format, feature U.S. coronavirus czar Dr. Anthony Fauci, Pfizer CEO
אלון נתנזון

Israeli startup MyHomeDoc receives FDA approval for smartphone-based telemedicine

06.04.21|CTech
The MyHomeDoc device is capable of testing the most common vital signs for primary medical care and all from a smartphone
פגישה וידאו עבודה מהבית

People learn more about a workplace in the hallways than in interviews

15.03.21|Maayan Manela
During a year of working remotely, many companies were forced to improve their recruitment process through apps, video interviews, and built-in digital questionnaires, which have forever changed the way companies sort through candidates
מגזין מנהלים 25.12.17 אני לא מסתנוור גיל שוויד

With the cloud blocking its horizon, Check Point is facing its moment of truth

11.03.21|Sophie Shulman
Under Gil Shwed's conservative leadership, the Israeli cybersecurity giant didn't capitalize fast enough on the cloud, leaving it to face some hard decisions
מפעל טבע טק נאות חובב פיטורים

Teva in talks with Covid-19 vaccine manufacturers to co-produce shots

10.02.21|Reuters and CTech
"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO
קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

Teva beats analysts predictions with increased revenues from growth drivers

10.02.21|Sophie Shulman
The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020
More Articles